Figure 4
From: Atp6ap2 ablation in adult mice impairs viability through multiple organ deficiencies
Bone-marrow reconstitution with Atp6ap2 cKO does not support full hematopoiesis upon tamoxifen treatment. (A) Experimental design for reconstitution of irradiated mice allowing 8 weeks for reconstitution (W0) and two weeks for immune-phenotyping after tamoxifen-treatment regimen (W2). Irradiated SJL CD45.1 host mice are reconstituted with either Atp4ap2 RosaTam CD45.2 or WT-CD45.2 BM cells. (B) Clinical blood counts from reconstituted Atp4ap2 RosaTam or WT-animals at W0 and after tamoxifen treatment (W2). (C,D) Hematopoietic lineage analysis expressed as a percentage of Atp6ap2 cKO over wild-type after tamoxifen treatment for (C) spleen [N = 3] or (D) blood [N = 3]. TAM, tamoxifen; RP, red pulp; pDC, plasmacytoid dendritic cells; NKc, natural killer cells; Tc, T lymphocytes; Bc, B lymphocytes.
